13 MAY 2026

FINANSIA
FSS INTERNATIONAL INVESTMENT ADVISORY

EQUITY RESEARCH - COMPANY REPORT

MEGA LIFESCIENCES MEGA TB

THAILAND / COMMERCE

การเติบโตของกำไรยังคงแข็งแกร่ง

- กำไรปกติกลับมาเติบโต y-y เป็นครั้งแรกในรอบ 5 ไตรมาส
- แบรนด์ Mega We Care ยังคงเป็นแรงขับเคลื่อนหลักของกำไร
- ความเสี่ยงในเมียนมาร์ที่ลดลง หนุนการปรับเพิ่มราคาเป้าหมายและคงคำแนะนำซื้อ

BUY

UNCHANGED

TARGET PRICE	THB43.00
CLOSE	THB37.75
UP/DOWNSIDE	+13.9%
PRIOR TP	THB39.00
CHANGE IN TP	+10.3%
TP vs CONSENSUS	+5.6%

กำไรปกติ 1Q26 กลับมาขยายตัว y-y

MEGA ประกาศกำไรสุทธิ 1Q26 ที่ 604.5 ล้านบาท สูงสุดในรอบ 5 ไตรมาส แต่มาจากกำไรจาก FX 40.1 ล้านบาท หักรายการพิเศษดังกล่าวออก เป็นกำไรปกติ 564.4 ล้านบาท -11.4% q-q ตามฤดูกาล แต่ +4.4% y-y กำไรกลับมาโต y-y เป็นครั้งแรกในรอบ 5 ไตรมาสจากการดำเนินงานในเมียนมาร์ที่ทยอยดีขึ้น ความแข็งแกร่งของแบรนด์ Mega We Care ควบคู่ไปกับการควบคุมค่าใช้จ่ายขายและบริหารอย่างมีประสิทธิภาพ กำไรไตรมาสนี้ถือว่าแข็งแกร่งเพราะอัตราภาษีจ่ายปรับขึ้นเป็น 23.5% หลังจากสิ้นสุดสิทธิประโยชน์ทางภาษีจาก BoI ตั้งแต่ 4Q25

แบรนด์ Mega We Care ยังคงเป็นแรงขับเคลื่อนหลัก

ธุรกิจ Brand มีรายได้เติบโตต่อเนื่องอย่างแข็งแกร่งด้วยเลขสองหลัก +16.5% y-y (-2.2% q-q ตามฤดูกาล) เป็น 2,341.4 ล้านบาท (68% ของรายได้รวม) เป็นแรงขับเคลื่อนหลัก และยังรักษาอัตรากำไรขั้นต้นไว้ได้ในระดับสูง 66.1% (ธุรกิจ Brand รักษาอัตรากำไรขั้นต้น 65-66% อย่างมีสเถียรภาพตลอด 5 ปีที่ผ่านมา)

การดำเนินงานที่ดีขึ้นในเมียนมาร์หนุนธุรกิจ Distribution

ธุรกิจ Distribution มีรายได้ +7.8% y-y เติบโตดีกว่าคาด สะท้อนการดำเนินงานที่ดีขึ้นในเมียนมาร์ ประกอบกับใน 1H25 เมียนมาร์ยังมีความเข้มงวดในมาตรการสินค้านำเข้าก่อนจะเริ่มผ่อนคลายตั้งแต่ 3Q25 แม้ว่าเมียนมาร์จะกลับมาเพิ่มความเข้มงวดในสินค้านำเข้าอีกครั้งเมื่อต้นปี 2026 แต่สินค้าของ MEGA ราว 80% ที่ส่งออกไปเมียนมาร์เป็นยาและอาหารเสริม อีก 20% เป็นสินค้าอุปโภค จึงได้รับผลกระทบจำกัดมาก อัตรากำไรขั้นต้นของธุรกิจ Distribution ลดลงจาก 23.5% ใน 1Q25 เป็น 21.8% เป็นผลจากค่าเงินและส่วนผสมของลูกค้า

ปรับเพิ่มราคาเป้าหมายจากความเสี่ยงที่ลดลง

กำไรปกติ 1Q26 คิดเป็น 23% ของประมาณการทั้งปี ความเสี่ยงด้านต้นทุนบรรจุภัณฑ์และค่าขนส่ง (รวมกัน 10% ของรายได้) ที่เป็นผลจากสงครามในตะวันออกกลาง จำกัดมากต่อ MEGA เราจึงคงประมาณการ แต่ปรับเพิ่มราคาเป้าหมายที่อิงวิธี DCF เป็น 43 บาท (จากเดิม 39 บาท) โดยปรับลด WACC เป็น 8.2% จากเดิม 8.6% สะท้อนความเสี่ยงของธุรกิจในเมียนมาร์ที่ลดลง ราคาเป้าหมายใหม่คิดเป็น 2026E implied P/E 15.0x (+0.5 SD) และ 2026E EV/EBITDA 9.4x ใกล้เคียงค่าเฉลี่ยในอดีต ถือว่าไม่แพงเกินไป และยังคงแนะนำซื้อ

KEY STOCK DATA

YE Dec (THB m)	2025	2026E	2027E	2028E
Revenue	14,147	15,003	15,588	16,294
Net profit	1,912	2,497	2,611	2,737
EPS (THB)	2.19	2.86	3.00	3.14
vs Consensus (%)	-	10.6	6.9	4.0
EBITDA	3,317	3,563	3,716	3,879
Recurring net profit	2,486	2,497	2,611	2,737
Core EPS (THB)	2.85	2.86	3.00	3.14
Chg. In EPS est. (%)	-	-	-	-
EPS growth (%)	(19.7)	0.5	4.6	4.8
Core P/E (x)	13.2	13.2	12.6	12.0
Dividend yield (%)	4.2	4.6	4.8	5.0
EV/EBITDA (x)	8.7	8.0	7.7	7.5
Price/book (x)	3.2	3.2	3.1	3.0
Net debt/Equity (%)	(38.6)	(41.0)	(38.9)	(36.9)
ROE (%)	24.7	24.3	24.9	25.5



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	10.2	(4.4)	24.8
Relative to country (%)	9.5	(9.9)	(0.1)

Mkt cap (USD m)	1,017
3m avg. daily turnover (USD m)	1.1
Free float (%)	40
Major shareholder	Unistretch Co Ltd (50%)
12m high/low (THB)	40.00/24.30
Issued shares (m)	871.87

Sources: Bloomberg consensus; FSSIA estimates

Jitra Amornthum
Fundamental Investment Analyst on Securities; License no. 014530
jitra.a@fssia.com, +66 2646 9966

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

บทวิเคราะห์ฉบับนี้แปลมาจากต้นฉบับภาษาอังกฤษ ที่ออกรายงานเมื่อวันที่ 13 พฤษภาคม 2026

Investment thesis

MEGA's earnings recovery became more evident in 1Q26, with core profit returning to y-y growth for the first time in five quarters despite a higher effective tax rate after the expiration of BoI privileges. Growth was driven by the strong performance of the high-margin Mega We Care brand, improving operations in Myanmar, and effective SG&A control.

We maintain our earnings forecasts and raise our DCF-based TP to THB43 to reflect lower Myanmar risk. Valuation remains attractive at 2026E P/E of 15.0x and EV/EBITDA of 9.4x, supporting our BUY rating.

Company profile

MEGA is a leading manufacturer and distributor of pharmaceutical, nutraceutical products and fast-moving consumer goods (FMCG) in developing countries such as Myanmar, Vietnam and Cambodia. MEGA also develops, manufactures, and sells its nutraceutical products, generic prescription pharmaceutical products, and OTC products under Mega We Care brand through its distribution network and third-party distributors in 36 countries across the world.

www.megawecare.com

Principal activities (revenue, 2025)



Source: Mega Lifesciences

Major shareholders



Source: Mega Lifesciences

Catalysts

Key potential catalysts include 1) a continued shift toward the higher-margin Mega We Care branded business, supporting margin expansion; 2) expansion into high-growth emerging markets; 3) recovery in the distribution business following normalisation in Myanmar and 4) expedited medicine registrations and listings, as well as the success of new product launches.

Risks to our call

Downside risks to our DCF-based TP include 1) the delayed registration process in many countries; 2) more intensified competition; 3) failure in introducing new products; and 4) risks associated with doing business in Myanmar.

Event calendar

Date	Event
28 May 2026	Earnings call

Key assumptions

	(unit)	2026E	2027E	2028E
Mega We Care	(THB m)	9,357	9,779	10,316
y-y Growth	*(%)*	*7.0*	*4.5*	*5.5*
Gross margin	(%)	64.4	64.5	64.4
Maxxcare	(THB m)	5,357	5,518	5,684
y-y Growth	*(%)*	*4.9*	*3.0*	*3.0*
Gross margin	(%)	32.1	32.0	32.0
SG&A to sales (%)	(%)	31.2	31.1	31.2

Source: FSSIA estimates

Earnings sensitivity

- For every 5% change in brand revenue, we project MEGA's 2026 net profit to change by 6%, all else being equal.
- For every 5% change in distribution revenue, we project MEGA's 2026 net profit to change by 1%, all else being equal.
- For every 1% change in overall gross margin, we project MEGA's 2026 net profit to change by 6%, all else being equal.

Source: FSSIA estimates

Earnings recovery gains traction

MEGA reported 1Q26 net profit of THB604.5m, the highest level in five quarters, supported by an FX gain of THB40.1m. Excluding the one-off item, core profit came in at THB564.4m, down 11.4% q-q on seasonality but up 4.4% y-y. This marks the first y-y earnings growth in five quarters, driven by the gradual recovery of operations in Myanmar, continued strength of the Mega We Care brand, and effective control of SG&A expenses. We view the 1Q26 earnings as particularly strong, given that the effective tax rate increased to 23.5% following the expiration of BoI tax privileges since 4Q25.

The Branded segment continued to deliver strong double-digit revenue growth of 16.5% y-y (-2.2% q-q due to seasonality) to THB2.3b, accounting for 68% of total revenue and remaining the key growth driver. The segment also maintained a high gross margin of 66.1%, in line with its consistently stable gross margin range of 65–66% over the past five years.

The Distribution business posted revenue growth of 7.8% y-y, exceeding expectations and reflecting improving operations in Myanmar. The comparison base was also relatively low, as Myanmar maintained strict import restrictions during 1H25 before easing measures from 3Q25 onward. Although the country reimposed tighter import controls in early 2026, the impact on MEGA remains limited, as around 80% of exports to Myanmar comprise pharmaceuticals and dietary supplements, while only 20% are consumer products.

Distribution gross margin declined to 21.8% from 23.5% in 1Q25, mainly due to currency effects and changes in customer mix.

SG&A expenses declined both q-q and y-y, accounting for 30.8% of revenue versus 33.2% in 1Q25, reflecting effective cost control.

Exhibit 1: MEGA – 1Q26 results summary

Year to Dec 31	1Q25	2Q25	3Q25	4Q25	1Q26	------ Change ------		2025	2026E	Change	% of
	(THB m)	(THB m)	(THB m)	(THB m)	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)	2026E
Sales	3,208	3,399	3,876	3,664	3,408	(7.0)	6.2	14,147	15,003	6.1	22.7
Cost of sales	(1,534)	(1,670)	(1,849)	(1,711)	(1,624)	(5.1)	5.9	(6,764)	(7,174)	6.1	22.6
Gross profit	1,673	1,729	2,027	1,954	1,784	(8.7)	6.6	7,383	7,830	6.0	22.8
Operating costs	(1,064)	(1,141)	(1,103)	(1,173)	(1,050)	(10.5)	(1.3)	(4,481)	(4,678)	4.4	22.4
Operating EBITDA	716	687	1,026	887	829	(6.6)	15.7	3,317	3,563	7.4	23.3
Interest expense	(9)	(13)	(15)	(18)	(15)	(15.5)	64.9	(55)	(64)	15.8	23.2
FX gain/loss	(91)	(106)	(317)	(60)	40	nm	nm	(574)	0	nm	nm
Tax	(83)	(118)	(129)	(162)	(175)	8.1	111.0	(492)	(692)	40.6	25.3
Reported net profit	**450**	**391**	**494**	**577**	**605**	***4.8***	***34.4***	**1,912**	**2,497**	***30.6***	***24.2***
Core profit	**541**	**497**	**811**	**637**	**564**	***(11.4)***	***4.4***	**2,486**	**2,497**	***0.5***	***22.6***
Reported EPS (THB)	0.52	0.45	0.57	0.66	0.69	4.8	34.4	2.19	2.86	30.6	24.2
Core EPS (THB)	0.62	0.57	0.93	0.73	0.65	(11.4)	4.4	2.85	2.86	0.5	22.6
Key Ratios	**(%)**	**(%)**	**(%)**	**(%)**	**(%)**	***(ppt)***	***(ppt)***	**(%)**	**(%)**	***(ppt)***	
Gross margin	52.2	50.9	52.3	53.3	52.3	(1.0)	0.2	52.2	55.3	3.2	
EBITDA margin	22.3	20.2	26.5	24.2	24.3	0.1	2.0	23.4	25.2	1.7	
Core profit margin	15.1	14.6	20.9	17.4	16.6	(0.8)	1.4	17.6	16.6	(0.9)	
SG&A / Sales	33.2	33.6	28.5	32.0	30.8	(1.2)	(2.4)	31.7	33.1	1.4	
Revenue breakdown	**(THB m)**	**(THB m)**	**(THB m)**	**(THB m)**	**(THB m)**	***(q-q %)***	***(y-y %)***	**(THB m)**	**(THB m)**	***(y-y %)***	
Branded business	1,984	2,193	2,189	2,363	2,310	(2.2)	16.5	8,729	9,357	7.2	
Distribution business	927	1,128	1,619	1,204	999	(17.1)	7.8	5,107	5,357	4.9	
OEM business	69	78	69	97	99	2.7	44.2	312	289	(7.6)	
Gross margin by business unit	**(%)**	**(%)**	**(%)**	**(%)**	**(%)**	***(ppt)***	***(ppt)***	**(%)**	**(%)**	***(ppt)***	
Branded business	65.0	62.7	65.6	65.0	66.1	1.1	1.1	64.6	64.4	(0.2)	
Distribution business	23.5	29.3	35.3	31.6	21.8	(9.8)	(1.7)	32.1	32.1	(0.1)	
OEM business	38.1	30.0	30.0	37.9	38.0	0.1	(0.1)	34.2	30.0	(4.2)	

Sources: MEGA, FSSIA estimates

Exhibit 2: Revenue structure and gross margin



Sources: MEGA, FSSIA's compilation

Exhibit 3: EBITDA margin and core profit



Sources: MEGA, FSSIA's compilation

Raising TP on improved risk profile

1Q26 core profit accounted for 23% of our full-year forecast. We believe risks from higher packaging and freight costs (combined at around 10% of revenue) arising from the Middle East conflict remain limited for MEGA. We therefore maintain our earnings forecasts, but raise our DCF-based TP to THB43 from THB39, driven by a lower WACC assumption of 8.2% (from 8.6%) to reflect reduced business risk in Myanmar.

Our new TP implies 2026E P/E of 15.0x (+0.5 SD) and 2026E EV/EBITDA of 9.4x, both broadly in line with historical averages and still not demanding. We reiterate our BUY rating.

Exhibit 4: DCF-based valuation

Cost of equity assumption	(%)	Cost of debt assumption	(%)
Risk free rate	3.0	Pre-tax cost of debt	4.5
Market risk premium	10.5	Tax rate	22.0
Stock beta	0.9		
Cost of equity, Ke	11.0	Cost of debt, Kd	1.0
Weight applied	66.5	Weight applied	33.5
WACC	8.2		
Terminal growth	3.00		
	(THB m)		
Sum of PV of FCF	10,254		
PV of Terminal value	27,548		
Enterprise value	37,802		
Net debt	(281)		
Equity value	37,521		
No. of shares	872		
Equity value per share	**43.04**		

Source: FSSIA estimates

Exhibit 5: One-year rolling forward P/E band



Sources: Bloomberg, FSSIA estimates

Exhibit 6: One-year rolling forward EV/EBITDA band



Sources: Bloomberg, FSSIA estimates

Financial Statements

Mega Lifesciences

Profit and Loss (THB m) Year Ending Dec	2024	2025	2026E	2027E	2028E
Revenue	15,344	14,147	15,003	15,588	16,294
Cost of goods sold	(7,590)	(6,764)	(7,174)	(7,438)	(7,749)
Gross profit	**7,754**	**7,383**	**7,830**	**8,150**	**8,545**
Other operating income	103	131	102	97	91
Operating costs	(4,385)	(4,481)	(4,678)	(4,848)	(5,084)
Operating EBITDA	**3,756**	**3,317**	**3,563**	**3,716**	**3,879**
Depreciation	(283)	(283)	(309)	(318)	(327)
Goodwill amortisation	0	0	0	0	0
Operating EBIT	**3,473**	**3,033**	**3,254**	**3,398**	**3,552**
Net financing costs	(38)	(55)	(64)	(63)	(52)
Associates	0	0	0	0	0
Recurring non-operating income	0	0	0	0	0
Non-recurring items	(1,082)	(574)	0	0	0
Profit before tax	**2,352**	**2,404**	**3,190**	**3,335**	**3,500**
Tax	(340)	(492)	(692)	(724)	(763)
Profit after tax	**2,013**	**1,912**	**2,497**	**2,611**	**2,737**
Minority interests	-	-	-	-	-
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	**2,013**	**1,912**	**2,497**	**2,611**	**2,737**
Non-recurring items & goodwill (net)	**1,082**	**574**	**0**	**0**	**0**
Recurring net profit	**3,095**	**2,486**	**2,497**	**2,611**	**2,737**
Per share (THB)					
Recurring EPS *	3.55	2.85	2.86	3.00	3.14
Reported EPS	2.31	2.19	2.86	3.00	3.14
DPS	1.60	1.60	1.72	1.80	1.88
Diluted shares (used to calculate per share data)	872	872	872	872	872
Growth					
Revenue (%)	(2.1)	(7.8)	6.1	3.9	4.5
Operating EBITDA (%)	14.3	(11.7)	7.4	4.3	4.4
Operating EBIT (%)	15.8	(12.6)	7.3	4.4	4.5
Recurring EPS (%)	14.7	(19.7)	0.5	4.6	4.8
Reported EPS (%)	1.0	(5.0)	30.6	4.6	4.8
Operating performance					
Gross margin inc. depreciation (%)	50.5	52.2	52.2	52.3	52.4
Gross margin exc. depreciation (%)	52.4	54.2	54.2	54.3	54.4
Operating EBITDA margin (%)	24.5	23.4	23.7	23.8	23.8
Operating EBIT margin (%)	22.6	21.4	21.7	21.8	21.8
Net margin (%)	20.2	17.6	16.6	16.8	16.8
Effective tax rate (%)	14.4	20.5	21.7	21.7	21.8
Dividend payout on recurring profit (%)	45.1	56.1	60.0	60.0	60.0
Interest cover (X)	90.2	55.1	51.0	54.0	68.1
Inventory days	160.1	171.0	164.4	164.2	161.1
Debtor days	81.3	88.1	80.9	73.1	72.9
Creditor days	140.2	157.5	168.0	158.9	148.2
Operating ROIC (%)	64.3	57.0	62.5	62.7	60.4
ROIC (%)	45.0	37.8	39.2	40.3	40.1
ROE (%)	32.3	24.7	24.3	24.9	25.5
ROA (%)	22.1	16.9	16.3	17.0	17.8

* Pre-exceptional, pre-goodwill and fully diluted

Revenue by Division (THB m)	2024	2025	2026E	2027E	2028E
Mega We Care	8,371	8,729	9,357	9,779	10,316
Maxxcare	6,667	5,107	5,357	5,518	5,684
OEM	306	312	289	291	294

Sources: Mega Lifesciences; FSSIA estimates

Financial Statements

Mega Lifesciences

Cash Flow (THB m) Year Ending Dec	2024	2025	2026E	2027E	2028E
Recurring net profit	3,095	2,486	2,497	2,611	2,737
Depreciation	283	283	309	318	327
Associates & minorities	0	0	0	0	0
Other non-cash items	(357)	(36)	44	20	(55)
Change in working capital	(509)	(36)	(669)	(1,113)	(1,103)
Cash flow from operations	**2,512**	**2,697**	**2,182**	**1,836**	**1,906**
Capex - maintenance	-	-	-	-	-
Capex - new investment	(230)	(664)	(309)	(330)	(350)
Net acquisitions & disposals	-	-	-	-	-
Other investments (net)	231	79	0	0	0
Cash flow from investing	**1**	**(585)**	**(309)**	**(330)**	**(350)**
Dividends paid	(1,395)	(1,395)	(1,498)	(1,567)	(1,642)
Equity finance	0	0	0	0	0
Debt finance	155	148	(6)	(12)	(180)
Other financing cash flows	(38)	(50)	(64)	(63)	(52)
Cash flow from financing	**(1,277)**	**(1,297)**	**(1,568)**	**(1,642)**	**(1,875)**
Non-recurring cash flows	-	-	-	-	-
Other adjustments	0	0	0	0	0
Net other adjustments	**(135)**	**0**	**0**	**0**	**0**
Movement in cash	**1,101**	**816**	**304**	**(136)**	**(319)**
Free cash flow to firm (FCFF)	2,552.10	2,167.83	1,936.25	1,569.17	1,608.09
Free cash flow to equity (FCFE)	2,495.78	2,210.83	1,802.52	1,430.97	1,323.41
Per share (THB)					
FCFF per share	2.93	2.49	2.22	1.80	1.84
FCFE per share	2.86	2.54	2.07	1.64	1.52
Recurring cash flow per share	3.46	3.14	3.27	3.38	3.45

Balance Sheet (THB m) Year Ending Dec	2024	2025	2026E	2027E	2028E
Tangible fixed assets (gross)	4,571	4,850	5,159	5,489	5,839
Less: Accumulated depreciation	(2,624)	(2,924)	(3,233)	(3,551)	(3,878)
Tangible fixed assets (net)	**1,947**	**1,925**	**1,926**	**1,938**	**1,961**
Intangible fixed assets (net)	**1,319**	**1,296**	**1,299**	**1,270**	**1,243**
Long-term financial assets	0	0	0	0	0
Invest. in associates & subsidiaries	40	37	37	37	37
Cash & equivalents	3,813	4,629	4,933	4,797	4,478
A/C receivable	3,264	3,566	3,083	3,160	3,348
Inventories	3,033	3,038	3,145	3,261	3,291
Other current assets	117	120	134	139	145
Current assets	**10,227**	**11,353**	**11,294**	**11,357**	**11,262**
Other assets	678	1,148	1,029	1,034	1,044
Total assets	**14,210**	**15,759**	**15,584**	**15,637**	**15,548**
Common equity	9,877	10,215	10,371	10,615	10,810
Minorities etc.	0	0	0	0	0
Total shareholders' equity	**9,877**	**10,215**	**10,371**	**10,615**	**10,810**
Long term debt	140	146	148	148	119
Other long-term liabilities	279	302	311	281	284
Long-term liabilities	**419**	**448**	**459**	**428**	**403**
A/C payable	2,416	3,175	3,145	3,057	2,972
Short term debt	351	537	530	518	366
Other current liabilities	1,146	1,383	1,081	1,019	998
Current liabilities	**3,914**	**5,096**	**4,755**	**4,593**	**4,336**
Total liabilities and shareholders' equity	**14,210**	**15,759**	**15,584**	**15,637**	**15,548**
Net working capital	2,851	2,165	2,136	2,484	2,814
Invested capital	6,834	6,572	6,426	6,764	7,100
* Includes convertibles and preferred stock which is being treated as debt					
Per share (THB)					
Book value per share	11.33	11.72	11.89	12.18	12.40
Tangible book value per share	9.82	10.23	10.40	10.72	10.97
Financial strength					
Net debt/equity (%)	(33.6)	(38.6)	(41.0)	(38.9)	(36.9)
Net debt/total assets (%)	(23.4)	(25.0)	(27.3)	(26.4)	(25.7)
Current ratio (x)	2.6	2.2	2.4	2.5	2.6
CF interest cover (x)	71.8	53.2	34.1	29.0	33.1

Valuation	2024	2025	2026E	2027E	2028E
Recurring P/E (x) *	**10.6**	**13.2**	**13.2**	**12.6**	**12.0**
Recurring P/E @ target price (x) *	**12.1**	**15.1**	**15.0**	**14.4**	**13.7**
Reported P/E (x)	16.4	17.2	13.2	12.6	12.0
Dividend yield (%)	4.2	4.2	4.6	4.8	5.0
Price/book (x)	3.3	3.2	3.2	3.1	3.0
Price/tangible book (x)	3.8	3.7	3.6	3.5	3.4
EV/EBITDA (x) **	7.9	8.7	8.0	7.7	7.5
EV/EBITDA @ target price (x) **	9.1	10.1	9.3	9.0	8.6
EV/invested capital (x)	4.3	4.4	4.5	4.3	4.1

* Pre-exceptional, pre-goodwill and fully diluted ** EBITDA includes associate income and recurring non-operating income

Sources: Mega Lifesciences; FSSIA estimates

MEGA LIFESCIENCES PCL (MEGA TB)

FSSIA ESG rating

★★★

Exhibit 7: FSSIA ESG score implication

56.39 /100

Rating	Score	Implication
★★★★★	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
★★★★	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
★★★	**>39-59**	**Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.**
★★	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
★	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Source: FSSIA estimates

Exhibit 8: ESG – peer comparison

	FSSIA	Domestic ratings						Global ratings						Bloomberg	
	ESG score	DJSI	SET ESG	SET ESG Rating	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BJC	78.20	Y	Y	AAA	5.00	4.00	--	Medium	68.83	AA	--	63.59	92.00	3.62	65.38
COM7	64.98	--	Y	AA	5.00	5.00	Certified	Low	50.61	--	--	55.64	32.00	5.80	59.98
CRC	84.99	Y	Y	AAA	5.00	5.00	Certified	Low	66.19	BBB	--	68.64	85.00	5.01	69.76
MEGA	56.39	--	Y	BBB	4.00	5.00	Certified	High	54.83	A	--	52.10	28.00	2.90	56.38

Sources: SETTRADE.com; FSSIA's compilation

Exhibit 9: ESG score by Bloomberg

FY ending Dec 31	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024
ESG financial materiality scores - ESG score	**—**	**2.29**	**2.27**	**2.42**	**2.90**
BESG environmental pillar score	—	1.86	1.78	1.99	3.18
BESG social pillar score	—	1.06	1.04	1.20	1.25
BESG governance pillar score	—	4.54	4.66	4.66	4.54
ESG disclosure score	**44.34**	**53.36**	**52.25**	**59.70**	**56.38**
Environmental disclosure score	29.84	44.22	43.43	51.53	40.05
Social disclosure score	19.44	32.16	29.59	37.61	45.41
Governance disclosure score	83.59	83.59	83.59	89.86	83.59
Environmental					
Emissions reduction initiatives	Yes	Yes	Yes	Yes	Yes
Climate change policy	Yes	Yes	Yes	Yes	Yes
Climate change opportunities discussed	No	No	No	No	No
Risks of climate change discussed	No	No	No	No	No
GHG scope 1	—	—	1	2	2
GHG scope 2 location-based	—	—	6	7	6
GHG Scope 3	—	—	0	0	0
Carbon per unit of production	—	—	—	—	—
Biodiversity policy	No	No	No	No	No
Energy efficiency policy	Yes	Yes	Yes	Yes	Yes
Total energy consumption	24	24	23	27	29
Renewable energy use	1	1	1	2	2
Electricity used	12	13	12	15	15
Fuel used - natural gas	—	—	31,112	35,936	1,083

Sources: Bloomberg; FSSIA's compilation

Exhibit 10: ESG score by Bloomberg *(cont.)*

FY ending Dec 31	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024
Fuel used - crude oil/diesel	No	No	No	No	No
Waste reduction policy	Yes	Yes	Yes	Yes	Yes
Hazardous waste	—	—	0	0	0
Total waste	1	1	1	1	1
Waste recycled	0	0	—	—	—
Waste sent to landfills	—	—	—	—	—
Environmental supply chain management	Yes	Yes	Yes	Yes	Yes
Water policy	No	Yes	Yes	Yes	Yes
Water consumption	—	—	70	86	93
Social					
Human rights policy	Yes	Yes	Yes	Yes	Yes
Policy against child labor	Yes	Yes	Yes	Yes	Yes
Quality assurance and recall policy	No	Yes	Yes	Yes	Yes
Consumer data protection policy	Yes	Yes	Yes	Yes	Yes
Equal opportunity policy	Yes	Yes	Yes	Yes	Yes
Gender pay gap breakout	No	No	No	No	No
Pct women in workforce	56	56	56	56	58
Pct disabled in workforce	—	—	—	—	—
Business ethics policy	Yes	Yes	Yes	Yes	Yes
Anti-bribery ethics policy	Yes	Yes	Yes	Yes	Yes
Health and safety policy	Yes	Yes	Yes	Yes	Yes
Lost time incident rate - employees	0	0	1	0	0
Total recordable incident rate - employees	—	—	—	0	0
Training policy	Yes	Yes	Yes	Yes	Yes
Fair remuneration policy	No	No	No	No	No
Number of employees – CSR	5,714	6,021	5,767	5,513	5,313
Employee turnover pct	—	19	—	25	23
Total hours spent by firm - employee training	70,551	79,892	70,826	83,494	74,549
Social supply chain management	Yes	Yes	Yes	Yes	Yes
Governance					
Board size	**10**	**10**	**10**	**11**	**11**
No. of independent directors (ID)	**4**	**4**	**4**	**5**	**5**
No. of women on board	1	1	1	2	2
No. of non-executive directors on board	8	8	8	9	9
Company conducts board evaluations	Yes	Yes	Yes	Yes	Yes
No. of board meetings for the year	6	5	7	7	7
Board meeting attendance pct	100	96	94	89	98
Board duration (years)	3	3	3	3	3
Director share ownership guidelines	No	No	No	No	No
Age of the youngest director	32	33	34	35	36
Age of the oldest director	80	81	82	83	84
No. of executives / company managers	**6**	**6**	**6**	**6**	**6**
No. of female executives	1	1	1	1	1
Executive share ownership guidelines	No	No	No	No	No
Size of audit committee	**3**	**3**	**3**	**3**	**3**
No. of ID on audit committee	3	3	3	3	3
Audit committee meetings	4	4	4	4	4
Audit meeting attendance %	100	100	100	100	92
Size of compensation committee	**3**	**3**	**3**	**3**	**3**
No. of ID on compensation committee	1	1	1	1	1
No. of compensation committee meetings	2	2	2	2	2
Compensation meeting attendance %	100	100	100	100	100
Size of nomination committee	**3**	**3**	**3**	**3**	**3**
No. of nomination committee meetings	2	2	3	2	2
Nomination meeting attendance %	100	100	100	100	100
Sustainability governance					
Verification type	No	No	No	Yes	No

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodology	Rating
The Dow Jones Sustainability Indices (DJSI) By S&P Global	The DJSI World applies a transparent, rules-based component selection process based on the companies' Total Sustainability Scores resulting from the annual S&P Global Corporate Sustainability Assessment (CSA). Only the top-ranked companies within each industry are selected for inclusion.	Be a member and invited to the annual S&P Global Corporate Sustainability Assessment (CSA) for DJSI. Companies with an S&P Global ESG Score of less than 45% of the S&P Global ESG Score of the highest scoring company are disqualified. The constituents of the DJSI indices are selected from the Eligible Universe.
SET ESG Ratings List (SETESG) by The Stock Exchange of Thailand (SET)	SET ESG quantifies responsibility in Environmental and Social issues by managing business with transparency in Governance, updated annually. Candidates must pass the preemptive criteria, with two crucial conditions: 1) no irregular trading of the board members and executives; and 2) free float of >150 shareholders, and combined holding must be >15% of paid-up capital. Some key disqualifying criteria include: 1) CG score of below 70%; 2) independent directors and free float violation; 3) executives' wrongdoing related to CG, social & environmental impacts; 4) equity in negative territory; and 5) earnings in red for > 3 years in the last 5 years.	To be eligible for **SETESG inclusion**, verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI during the assessment year. The scoring will be fairly weighted against the nature of the relevant industry and materiality. **SETESG Index** is extended from the SET ESG Ratings companies whose 1) market capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight at maximum, and no cap for number of stocks.
CG Score by Thai Institute of Directors Association (Thai IOD)	An indicator of CG strength in sustainable development, measured annually by the Thai IOD, with support from the Stock Exchange of Thailand (SET). The results are from the perspective of a third party, not an evaluation of operations.	Scores are rated in six categories: 5 for Excellent (90-100), 4 for Very Good (80-89), 3 for Good (70-79), 2 for Fair (60-69), 1 for Pass (60-69), and not rated for scores below 50. Weightings include: 1) the rights; 2) and equitable treatment of shareholders (weight 25% combined); 3) the role of stakeholders (25%); 4) disclosure & transparency (15%); and 5) board responsibilities (35%).
AGM level By Thai Investors Association (TIA) with support from the SEC	It quantifies the extent to which shareholders' rights and equitable treatment are incorporated into business operations and information is transparent and sufficiently disclosed. All form important elements of two out of five the CG components to be evaluated annually. The assessment criteria cover AGM procedures before the meeting (45%), at the meeting date (45%), and after the meeting (10%). (*The first assesses 1) advance circulation of sufficient information for voting; and 2) facilitating how voting rights can be exercised. The second assesses 1) the ease of attending meetings; 2) transparency and verifiability; and 3) openness for Q&A. The third involves the meeting minutes that should contain discussion issues, resolutions and voting results.)*	The scores are classified into four categories: 5 for Excellent (100), 4 for Very Good (90-99), 3 for Fair (80-89), and not rated for scores below 79.
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	The core elements of the Checklist include corruption risk assessment, establishment of key controls, and the monitoring and developing of policies. The Certification is good for three years. *(Companies deciding to become a CAC certified member start by submitting a Declaration of Intent to kick off an 18-month deadline to submit the CAC Checklist for Certification, including risk assessment, in place of policy and control, training of managers and employees, establishment of whistleblowing channels, and communication of policies to all stakeholders.)*	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.
Morningstar Sustainalytics	The Sustainalytics' ESG risk rating provides an overall company score based on an assessment of how much of a company's exposure to ESG risk is unmanaged. *Sources to be reviewed include corporate publications and regulatory filings, news and other media, NGO reports/websites, multi-sector information, company feedback, ESG controversies, issuer feedback on draft ESG reports, and quality & peer reviews.*	A company's ESG risk rating score is the sum of unmanaged risk. The more risk is unmanaged, the higher ESG risk is scored. NEGL: 0-10 / Low: 10-20 / Medium: 20-30 / High: 30-40 / Severe: 40+
ESG Book	The ESG score identifies sustainable companies that are better positioned to outperform over the long term. The methodology considers the principle of financial materiality including information that significantly helps explain future risk-adjusted performance. Materiality is applied by over-weighting features with higher materiality and rebalancing these weights on a rolling quarterly basis.	The total ESG score is calculated as a weighted sum of the features scores using materiality-based weights. The score is scaled between 0 and 100 with higher scores indicating better performance.
MSCI	MSCI ESG ratings aim to measure a company's management of financially relevant ESG risks and opportunities. It uses a rules-based methodology to identify industry leaders and laggards according to their exposure to ESG risks and how well they manage those risks relative to peers. AAA 8.571-10.000 AA 7.143-8.570 A 5.714-7.142 BBB 4.286-5.713 BB 2.857-4.285 B 1.429-2.856 CCC 0.000-1.428	**Leader:** leading its industry in managing the most significant ESG risks and opportunities **Average:** a mixed or unexceptional track record of managing the most significant ESG risks and opportunities relative to industry peers **Laggard:** lagging its industry based on its high exposure and failure to manage significant ESG risks
Moody's ESG solutions	Moody's assesses the degree to which companies take into account ESG objectives in the definition and implementation of their strategy policies. It believes that a company integrating ESG factors into its business model and relatively outperforming its peers is better positioned to mitigate risks and create sustainable value for shareholders over the medium to long term.	
Refinitiv ESG rating	Designed to transparently and objectively measure a company's relative ESG performance, commitment and effectiveness across 10 main themes, based on publicly available and auditable data. The score ranges from 0 to 100 on relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly. *(Score ratings are 0 to 25 = poor; >25 to 50 = satisfactory; >50 to 75 = good; and >75 to 100 = excellent.)*	
S&P Global	The S&P Global ESG Score is a relative score measuring a company's performance on and management of ESG risks, opportunities, and impacts compared to its peers within the same industry classification. The score ranges from 0 to 100.	
Bloomberg	ESG Score	Bloomberg score evaluating the company's aggregated Environmental, Social and Governance (ESG) performance. The score is based on Bloomberg's view of ESG financial materiality. The score is a weighted generalized mean (power mean) of Pillar Scores, where the weights are determined by the pillar priority ranking. Values range from 0 to 10; 10 is the best.
Bloomberg	ESG Disclosure Score	Disclosure of a company's ESG used for Bloomberg ESG score. The score ranges from 0 for none to 100 for disclosure of every data point, measuring the amount of ESG data reported publicly, and not the performance on any data point.

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "**CG Score**"; 2) "**AGM Level**"; 3) "**Thai CAC**"; and 4) ""**SETESG**" The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Jitra Amornthum FSS International Investment Advisory Securities Co., Ltd

Finansia Syrus Securities Public Company Limited and FSS International Investment Advisory Securities Company Limited are subsidiaries of Finansia X Public Company Limited, with shared directors or executives.

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price

Mega Lifesciences (MEGA TB)



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
04-Aug-2023	BUY	65.00	25-Feb-2025	BUY	40.00	11-Feb-2026	HOLD	39.00
17-Nov-2023	BUY	56.00	30-Apr-2025	BUY	36.00	25-Mar-2026	BUY	39.00
12-Dec-2024	BUY	45.00	31-Oct-2025	BUY	33.00			

Jitra Amornthum started covering this stock from 20-Feb-2023

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Mega Lifesciences	MEGA TB	THB 37.75	BUY	Downside risks to our DCF-based TP include 1) the delayed registration process in many countries; 2) more intensified competition; 3) failure in introducing new products; and 4) risks associated with doing business in Myanmar.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 13-May-2026 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.
HOLD (H). The upside or downside is less than 10%.
REDUCE (R). The downside is 10% or more.
Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.
Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.
Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.